---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-010055"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2023-04-12T23:59:59+00:00"
generated_at: "2026-06-17T02:57:04.562757+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Dyadic expands C1 platform licensing deal with Rubic One Health for Africa vaccines and biologics

## Summary
- Expanded license covers vaccines and therapeutic proteins beyond COVID-19 for human and animal health.
- Rubic to pay licensing fee on commercial sales; Dyadic receives equity in Rubic in 2028.
- Milestones allow conversion to exclusive license for bulk manufacturing in SADC region.
- DYAI-100 (COVID-19 vaccine candidate) is in Phase 1 first-in-human trial, enabling the expansion.
- Agreement aims to develop affordable biologics for underserved African countries.

## SEC filing metadata
- accession: 0001437749-23-010055
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2023-04-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000143774923010055/0001437749-23-010055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000143774923010055/dyai20230410_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-010055
- JSON: https://secwatch.observer/filing/0001437749-23-010055.json
- Plain text: https://secwatch.observer/filing/0001437749-23-010055.txt

## Key facts
- Material Agreements
  DYADIC INTERNATIONAL INC entered into Expanded Licensing Agreement with Rubic One Health (effective 2023-04-06).
  - Action: entry
  - Agreement: license
  - Counterparty: Rubic One Health
  - Effective: 2023-04-06
  source text: On April 6, 2023, Dyadic International (USA), Inc., a subsidiary of Dyadic International, Inc., (hereinafter collectively referred to as “Dyadic” or the “Company”) signed an expanded licensing agreement (“the Agreement”) for its C1-cell protein expression platform with South Africa’s Rubic One Health (“Rubic”) to research, develop, manufacture, commercialize and distribute affordable vaccines and biologics for human and animal health in underserved African countries.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213809/000143774923010055/0001437749-23-010055-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.